MedPath

FDA Approves Evolus' Novel Hyaluronic Acid Dermal Fillers with Superior Efficacy Profile

  • Evolus, Inc. receives FDA approval for two new injectable hyaluronic acid dermal fillers, Evolysse Form and Evolysse Smooth, marking their entry into the dermal filler market.

  • A pivotal clinical study of 140 patients demonstrated statistical superiority (P < .001) of both Evolysse products compared to Restylane-L in treating nasolabial folds.

  • Both products showed comparable safety profiles to Restylane-L with only mild-to-moderate adverse events, and Evolysse Smooth achieved its results using 20% less product.

Evolus, Inc. has secured FDA approval for two innovative injectable hyaluronic acid dermal fillers, Evolysse Form and Evolysse Smooth, marking a significant expansion into the aesthetic dermatology market. The approval follows successful clinical trials demonstrating superior efficacy in treating nasolabial folds compared to existing treatments.

Clinical Trial Results Demonstrate Superior Efficacy

In a rigorous U.S. Nasolabial Fold study, researchers conducted a randomized, double-blind, prospective, active-control split-face trial involving 140 participants. The study, led by Dr. Michael Kaminer, compared both new fillers head-to-head with Restylane-L, a current market standard.
"The Evolysse Form and Evolysse Smooth injectable HA gels demonstrated impressive safety, efficacy, and versatility, with the unique property of being injectable at various depths in the skin," stated Dr. Kaminer, the study's lead investigator. "These products allow practitioners to achieve precise, natural-looking results, while delivering high patient satisfaction with their effectiveness and longevity."

Superior Performance Metrics

Statistical analysis revealed significant advantages for both new products. Evolysse Form demonstrated superior performance compared to Restylane-L consistently throughout the 12-month study period. Notably, Evolysse Smooth showed better results at both 6 and 9-month intervals while requiring 20% less product volume for comparable outcomes.

Safety Profile and Market Impact

The safety assessment revealed comparable profiles between the new products and Restylane-L. Adverse events were predominantly mild to moderate, with no serious treatment-related complications reported. Importantly, no cases of delayed-onset nodules were observed during the study period.

Product Launch Timeline

Evolus plans to launch both dermal filler products in the second quarter of 2025, adding to their portfolio of aesthetic treatments. This strategic expansion into the hyaluronic acid dermal filler market positions Evolus as a more comprehensive provider of aesthetic solutions.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Approves Journey Medical's Emrosi (Minocycline HCl) for Rosacea

The FDA has approved Journey Medical's Emrosi (minocycline hydrochloride extended-release capsules, 40 mg) for treating inflammatory lesions of rosacea in adults.

FDA Approves Journey Medical's Emrosi™ for Rosacea Treatment

Journey Medical's Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) receives FDA approval for treating inflammatory lesions of rosacea in adults.

FDA Approves New Intravenous Formulation of Ustekinumab Biosimilar SELARSDI™

The FDA has approved a new intravenous formulation of SELARSDI™ (ustekinumab-aekn), a biosimilar to STELARA® (ustekinumab), expanding its potential use.

FDA Approves New IV Formulation of Selarsdi (ustekinumab-aekn) for Expanded Indications

The FDA has approved a new intravenous formulation of Selarsdi (ustekinumab-aekn), a biosimilar to Stelara, expanding its potential uses.

FDA Approves New IV Infusion Presentation of Selarsdi (ustekinumab-aekn) Biosimilar

The FDA has approved a new intravenous infusion formulation of Selarsdi (ustekinumab-aekn), a biosimilar to Stelara, expanding its potential use.

Establishment Labs Gains FDA Approval for Motiva Breast Implants

Establishment Labs has received FDA approval for its Motiva SmoothSilk Ergonomix and Round breast implants for primary and revision augmentation.

FDA Approves Eli Lilly's Ebglyss (lebrikizumab) for Eczema Treatment in Adults and Children

The FDA has approved Eli Lilly's Ebglyss (lebrikizumab) for treating moderate-to-severe eczema in adults and children aged 12 and older.

FDA Approves Pavblu, Fifth Biosimilar to Eylea, for Retinal Conditions

The FDA has approved Pavblu (aflibercept-ayyh) as a biosimilar to Eylea (aflibercept) for treating retinal conditions..

FDA Approves Ahzantive, a Biosimilar to Eylea, for Retinal Diseases

The FDA has approved Ahzantive (aflibercept-mrbb) as a biosimilar to Eylea for treating retinal diseases.

FDA Approves Alvotech/Teva's Ustekinumab Biosimilar for Psoriasis and Psoriatic Arthritis

The FDA has approved SELARSDI (ustekinumab-aekn), a biosimilar developed by Alvotech and commercialized by Teva, for treating moderate to severe plaque psoriasis and active psoriatic arthritis in adults and pediatric patients aged 6 and older.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy